Delcath Systems Inc. (US24661P8077)
XSTU 
Summary
US24661P8077 Chart
Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Delcath Systems Inc. (US24661P8077) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Delcath Systems Inc. ever had a stock split?
Delcath Systems Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Gerard J. Michel CEO | XSTU Exchange | US24661P8077 ISIN |
| US Country | 156 Employees | - Last Dividend | 24 Dec 2019 Last Split | - IPO Date |
Overview
Delcath Systems, Inc. is an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers primarily within the United States and Europe. Since its incorporation in 1988, the company has been focused on developing innovative treatments that aim to improve the quality of life for patients afflicted with liver cancer. With its headquarters located in New York, New York, Delcath Systems, Inc. has been at the forefront of delivering targeted therapies for liver cancer patients, striving to limit systemic exposure and reduce the side effects commonly associated with high-dose chemotherapy treatments.
Products and Services
- HEPZATO KIT
This lead product candidate from Delcath Systems, Inc. is a combination of melphalan for injection and a hepatic delivery system designed to administer high-dose chemotherapy directly to the liver, thereby controlling systemic exposure and minimizing associated side effects. It embodies the company's dedication to interventional oncology by offering a targeted treatment approach for liver cancer patients.
- FOCUS Clinical Trial
As part of its clinical development program for HEPZATO, the FOCUS clinical trial represents Delcath's commitment to advancing the treatment of metastatic hepatic dominant Uveal Melanoma. This trial aims to investigate the objective response rate in patients with metastatic uveal melanoma, underscoring the company’s focus on addressing this challenging cancer subtype through innovative treatment methodologies.
- CHEMOSAT Hepatic Delivery System for Melphalan/CHEMOSAT
In Europe, Delcath provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan, or simply CHEMOSAT. This allows medical centers across Europe to treat a variety of liver cancers with a system that is designed to deliver high-dose chemotherapy directly to the liver, targeting cancer cells more effectively while sparing the rest of the body from the harsh effects of chemotherapy.
